143 related articles for article (PubMed ID: 27027386)
1. Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.
Pedersen J; Lundbo LF; Krarup H; Bukh J; Weis N
J Med Virol; 2016 Oct; 88(10):1791-803. PubMed ID: 27027386
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
Pedersen J; Jensen TB; Carlsen TH; Schønning K; Christensen PB; Laursen AL; Krarup H; Bukh J; Weis N
PLoS One; 2013; 8(5):e62674. PubMed ID: 23667506
[TBL] [Abstract][Full Text] [Related]
3. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
[TBL] [Abstract][Full Text] [Related]
4. IgG1 and IgG4 antibodies against Core and NS3 antigens of hepatitis C virus.
Santos VCD; Schinoni MI; Oliveira IS; Atta MLS; Atta AM
Rev Soc Bras Med Trop; 2019 Mar; 52():e20180491. PubMed ID: 30843970
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of occult hepatitis C virus infection in the Iranian patients with human immunodeficiency virus infection.
Bokharaei-Salim F; Keyvani H; Esghaei M; Zare-Karizi S; Dermenaki-Farahani SS; Hesami-Zadeh K; Fakhim S
J Med Virol; 2016 Nov; 88(11):1960-6. PubMed ID: 27463051
[TBL] [Abstract][Full Text] [Related]
6. Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.
Maurin G; Halgand B; Bruscella P; Fresquet J; Duclos-Vallée JC; Roque-Afonso AM; Cosset FL; Samuel D; Lavillette D; Féray C
AIDS; 2015 Jun; 29(9):1025-33. PubMed ID: 26125137
[TBL] [Abstract][Full Text] [Related]
7. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
[TBL] [Abstract][Full Text] [Related]
8. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
[TBL] [Abstract][Full Text] [Related]
9. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease.
Masarone M; La Mura V; Bruno S; Gaeta GB; Vecchione R; Carrino F; Moschella F; Torella R; Persico M
J Viral Hepat; 2007 Oct; 14(10):714-20. PubMed ID: 17875006
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.
Meuleman P; Bukh J; Verhoye L; Farhoudi A; Vanwolleghem T; Wang RY; Desombere I; Alter H; Purcell RH; Leroux-Roels G
Hepatology; 2011 Mar; 53(3):755-62. PubMed ID: 21319203
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection.
Kanno A; Kazuyama Y
J Med Virol; 2002 Oct; 68(2):229-33. PubMed ID: 12210412
[TBL] [Abstract][Full Text] [Related]
12. Japan-specific subtype of hepatitis C virus genotype 1b, J subtype, has relatively low pathogenicity.
Nakano I; Fukuda Y; Katano Y; Toyoda H; Hayashi K; Kumada T; Nakano S
J Med Virol; 2001 Sep; 65(1):45-51. PubMed ID: 11505442
[TBL] [Abstract][Full Text] [Related]
13. Antigenic relevance of F protein in chronic hepatitis C virus infection.
Komurian-Pradel F; Rajoharison A; Berland JL; Khouri V; Perret M; Van Roosmalen M; Pol S; Negro F; Paranhos-Baccalà G
Hepatology; 2004 Oct; 40(4):900-9. PubMed ID: 15382175
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of antibodies to core+1/ARF protein in HCV-infected patients with advanced cirrhosis.
Kassela K; Karakasiliotis I; Charpantidis S; Koskinas J; Mylopoulou T; Mimidis K; Sarrazin C; Grammatikos G; Mavromara P
J Gen Virol; 2017 Jul; 98(7):1713-1719. PubMed ID: 28708052
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus serotypes in Romanian patients with chronic hepatitis and cirrhosis.
Iancu LS; Pandele GI; Stanciu C; Luca V
Rev Med Chir Soc Med Nat Iasi; 2002; 106(1):79-82. PubMed ID: 12635365
[TBL] [Abstract][Full Text] [Related]
16. Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.
Lin J; Wang W; Xu Y; Di Bisceglie AM; Fan X
J Med Virol; 2015 May; 87(5):821-8. PubMed ID: 25652546
[TBL] [Abstract][Full Text] [Related]
17. Correlation between histologic staging, hepatitis C virus genotypes and clinical features in HCV chronic hepatitis: evidence of a new pattern.
Di Tommaso L; Macchia S; Morandi L; Leoncini S; Pession A; Dal Monte PR; Foschini MP
Int J Surg Pathol; 2003 Jul; 11(3):197-204. PubMed ID: 12894351
[TBL] [Abstract][Full Text] [Related]
18. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of serum IgG, IgA and IgM levels as indicators of hepatic fibrosis in patients with chronic hepatitis C infection].
Ortarık Z; Toyran A; Sen S; Mart Kömürcü SZ; Güvener E
Mikrobiyol Bul; 2011 Apr; 45(2):296-305. PubMed ID: 21644073
[TBL] [Abstract][Full Text] [Related]
20. Liver fibrosis progression in hepatitis C virus infection after seroconversion.
Butt AA; Yan P; Lo Re V; Rimland D; Goetz MB; Leaf D; Freiberg MS; Klein MB; Justice AC; Sherman KE;
JAMA Intern Med; 2015 Feb; 175(2):178-85. PubMed ID: 25485735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
